Grufity logo
Grufity logo
NOTV

NOTV - Inotiv, Inc. Stock Price, Fair Value and News

$0.01 
Market Closed as of 27 Jul 2026, 04:00 pm ET

NOTV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NOTV Price Action

Last 90 days

-96.5%

Trailing 12 Months

-99.6%

NOTV RSI Chart

NOTV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NOTV Valuation

Market Cap

348.9K

Price/Earnings (Trailing)

0

Price/Sales (Trailing)

7e-4

EV/EBITDA

57.42

Price/Free Cashflow

0.99

NOTV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NOTV Fundamentals

NOTV Revenue

Revenue (TTM)

507.4M

Rev. Growth (Yr)

-5.37%

Rev. Growth (Qtr)

-2.67%

NOTV Earnings

Earnings (TTM)

-87.0M

Earnings Growth (Yr)

-118.4%

Earnings Growth (Qtr)

-14.41%

NOTV Profitability

EBT Margin

-20.84%

Return on Equity

-112.81%

Return on Assets

-12.38%

Free Cashflow Yield

101.47%

NOTV Investor Care

Shares Dilution (1Y)

2.63%

Diluted EPS (TTM)

-2.46

Revenue & Growth

How Inotiv, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026507.4M---
2025480.4M505.3M513.0M514.0M
2024552.7M501.1M490.7M475.1M
2023597.3M582.2M572.4M585.2M
2022277.5M427.3M547.7M586.2M
202168.2M75.3M89.6M155.9M
202054.6M59.5M60.5M65.4M
201933.0M36.5M43.6M49.1M
201823.0M23.2M26.3M29.6M
201722.7M23.5M24.2M23.4M
201621.4M20.3M20.4M21.7M
201524.0M24.1M22.7M21.7M
201423.2M23.7M24.6M24.2M
201324.7M23.1M22.1M22.5M
201231.1M29.8M28.2M26.5M
2011--33.1M32.6M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Inotiv, Inc.

NOTV
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment, Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services including, computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes, general and genetic toxicology, regulated bioanalysis, biotherapeutics, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes, nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
 CEO
 WEBSITEinotivco.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES2099

Inotiv, Inc. Frequently Asked Questions

NOTV is the stock ticker symbol of Inotiv, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jul 27 2026, market cap of Inotiv, Inc. is 348.88 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jul 27 2026, NOTV's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NOTV PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Inotiv, Inc. has provided -0.39 (multiply by 100 for percentage) rate of return.